Acumen pharmaceuticals presents in vitro human neuron model for evaluating binding of amyloid beta oligomers in alzheimer's disease

Charlottesville, va. and carmel, ind., march 28, 2023 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos) (“acumen” or the “company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic globular soluble amyloid beta oligomers (saΒos) for the treatment of alzheimer's disease (ad), has demonstrated the utility of a human in vitro model of ipsc-derived excitatory neurons for a better understanding of which forms of amyloid beta oligomers contribute to the pathogenesis of ad in the human brain. this research will be presented in a poster at the international conference on alzheimer's and parkinson's diseases and related neurological disorders (ad/pd), held in-person in gothenburg, sweden, and virtually march 28 – april 1, 2023.
ABOS Ratings Summary
ABOS Quant Ranking